Abstract
Introduction New vaccines, technologies, and regulations, alongside increased demand for vaccines, all require prioritization and coordination from key players within the vaccine sector. Inter-agency Coordinating Committees (ICC) are forums used to support decision-making and coordination at the national-level and act as key drivers for sustainable improvements in vaccination programming. However, literature examining the functionality of ICCs is limited and outdated.
Methods We employed a qualitative case study design to investigate critical success factors for high and sustained routine immunization coverage in Zambia from 2000-2018.Qualitative data were collected between October 2019 and February 2020, including key informant interviews (n=66) at the national, provincial, district, and health facility levels. Thematic analysis was applied to understand the role of the Zambia ICC and its impact on the policy environment overtime.
Results Throughout our study period, particularly from 2014 to present, the Zambian ICC has demonstrated the following improvements: 1) expanded membership to include diverse representation; 2) expanded scope and mandate to include maternal and child health in decision-making; and 3) effective collaboration with the NITAG through distinct and complimentary roles and responsibilities. The Zambian ICC holds considerable influence on government agencies and external partners, which facilitates the procurement of funding, policy decisions, and strategic planning – therefore contributing to the high routine immunization coverage.
Conclusion Findings from this paper may contribute to decision-making processes, long-term engagement, membership, and mandates for ICCs in other countries. Transferable lessons include: 1) Expand ICC membership to include a variety of government officials, local representatives, community organizations, external partners, and donors to foster coordination and collaboration across stakeholders; 2) Expand ICC mandate and scope to include other areas of health (i.e., reproductive, maternal, and child health) to foster integration of programs and health systems strengthening; and 3) Establish distinct and complementary roles and responsibilities for the ICC and NITAG to ensure efficient, collaborative, and sustainable integration.
Article Summary – Strengths and Weaknesses of Methods
Zambia was identified as an exemplar in vaccine delivery through analysis of DTP1 and DTP3 coverage from 2000 to 2018, compared to other similar countries – therefore, we were able to identify factors that contributed to effective vaccination programming, which included national-level coordination through the ICC. However, we were unable to carry out a similar analysis in a non-exemplary country to compare immunization coverage.
We interviewed a wide-range of key informants (n=66) to understand diverse perspectives – including representatives from different levels of the health system and from external partner organizations.
All interview guides were piloted before use and adjusted iteratively throughout data collection. Debriefs were conducted during data collection to identify emerging themes and follow-up questions. However, the research tools focused on the factors that drove catalytic change and did not probe on interventions or policies that were unsuccessful.
Initial findings were shared with a research advisory group composed of international and Zambian stakeholders and experts within the governance, policy, and immunization sectors. Findings from the qualitative data were also triangulated with information from Gavi documents to strengthen the analysis.
Using qualitative methods to understand historical events was challenging; interviewees often spoke about current experiences rather than discussing historical factors. However, research assistants probed respondents to reflect on longitudinal changes in the immunization program.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding from the Bill and Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of Zambia Biomedical Research Ethics Committee (Federal Assurance No. FWA00000338, REF. No. 166-2019), the National Health Research Authority in Zambia, and the Institutional Review Board committee of Emory University, Atlanta, Georgia, USA (IRB00111474).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figures added to the main text.
Data Availability
available upon request
